Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Bull of the Day: Credo Technology (CRDO)

View original at nasdaq.com
Bull of the Day: Credo Technology (CRDO) Credo Technology Group (CRDO) is a key supplier of high-performance serial connectivity solutions for the hyperscale datacenter, 5G carrier, enterprise networking, HPC (high-performance computing), and AI/ML markets…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Credo aims to break bandwidth barriers in the data infrastructure market and provides secure, high-speed connectivity solutions that deliver improved power efficiency

    80% confidence
  • Amazon may have contributed as much as 85% of Credo's Q3 topline revenue, though Credo did not officially disclose this

    80% confidence
  • Jensen talks about 1,000-fold advances in science, engineering, and social challenges due to NVIDIA's simulation and synthetic data capabilities

    80% confidence
  • Many important trends are driving the data infrastructure market, such as cloud workloads, streaming video, 5G wireless deployment, IoT expansion, and growing adoption of AI, creating an explosion of data that has stressed existing infrastructure

    80% confidence
  • CRDO is a buy in the $40s price range

    80% confidence
  • NVIDIA has been creating new industries for almost eight years, with Jensen & Co. developing use cases by the thousands per year once data enterprises and universities caught on to GPU-CUDA capabilities

    80% confidence
  • Credo had seven customers that contributed more than 5% of revenue, and going forward expects three to four customers will be greater than 10% of revenue in coming quarters and fiscal year as additional hyperscalers ramp to more significant volumes

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com